Article
Oncology
Michael W. Caminear, Brittney S. Harrington, Rahul D. Kamdar, Michael J. Kruhlak, Christina M. Annunziata
Summary: The study found that disulfiram was more effective in reducing the viability of TICs compared to NCTs, affecting NF kappa B signaling, and was more suitable as a therapeutic to prevent EOC relapse.
FRONTIERS IN ONCOLOGY
(2022)
Article
Cell Biology
Yuxuan Luo, Ying Lu, Bing Long, Yansi Lin, Yanling Yang, Yichuang Xu, Xiangzhong Zhang, Jingwen Zhang
Summary: The FLT3-ITD mutation is associated with poor prognosis in AML, and treatment includes the use of FLT3 inhibitors. This study found that the STAT3 inhibitor Stattic can affect AML cells by inhibiting proliferation, promoting apoptosis, and arresting the cell cycle, as well as suppressing DNA damage repair mechanisms.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Oncology
Martina K. Zowada, Stephan M. Tirier, Sebastian M. Dieter, Teresa G. Krieger, Ava Oberlack, Robert Lorenz Chua, Mario Huerta, Foo Wei Ten, Karin Laaber, Jeongbin Park, Katharina Jechow, Torsten Mueller, Mathias Kalxdorf, Mark Kriegsmann, Katharina Kriegsmann, Friederike Herbst, Jeroen Krijgsveld, Martin Schneider, Roland Eils, Hanno Glimm, Christian Conrad, Claudia R. Ball
Summary: Different cell types with tumor-initiating cell (TIC) activity in colorectal cancer (CRC) show distinct gene expression patterns at single-cell level. Metabolic states are closely linked to TIC activity in primary CRC cultures, suggesting oxidative phosphorylation as a potential target for novel therapies. Transcriptional heterogeneity at single-cell resolution identifies functional states during TIC differentiation and may reveal novel vulnerabilities in human CRC.
Article
Biochemistry & Molecular Biology
Dipak K. Poria, Namratha Sheshadri, Kuppusamy Balamurugan, Shikha Sharan, Esta Sterneck
Summary: Stattic, known as a specific STAT3 inhibitor, has additional effects on cancer cells independent of STAT3, such as attenuating histone acetylation, activating specific gene expression, promoting autophagy, and inducing cell death. This suggests a polypharmacological role of Stattic and related compounds in targeting cancer cells through multi-pronged cytotoxic effects.
JOURNAL OF BIOLOGICAL CHEMISTRY
(2021)
Article
Medicine, Research & Experimental
Yong-An Lee, Chee Chong Jonathan, Gao Rong, Zhengwei Wu, S. Shathishwaran, Jia Hui Jane Lee, Wai Leong Tam, Torsten Wuestefeld, Sung-Jin Park, Sangyong Jung, Beomsue Kim, Nam -Young Kang, Young -Tae Chang
Summary: The study aims to assess the applicability of TiY in theranostics, from in vivo visualization to therapeutic effect towards tumor-initiating cells (TIC) in cancer mouse models. Through cell experiments and animal model studies, we demonstrated the selective identification and therapeutic effect of TiY on TIC in animal models.
Review
Medicine, Research & Experimental
Mehrdokht Sadrkhanloo, Mahshid Deldar Abad Paskeh, Mehrdad Hashemi, Rasoul Raesi, Motahhar Motahhary, Sam Saghari, Laleh Sharifi, Saied Bokaie, Sepideh Mirzaei, Maliheh Entezari, Amir Reza Aref, Shokooh Salimimoghadam, Mohsen Rashidi, Afshin Taheriazam, Kiavash Hushmandi
Summary: Prostate cancer is the most common malignancy in men, causing high death rates annually. Diagnosis of prostate cancer relies on biomarkers like the PSA test, and prognosis is usually poor. The cancer cells spread rapidly and metastasis is a major cause of death. Current therapies include chemotherapy, surgery, radiotherapy, and targeted therapy. The progression of prostate cancer cells involves factors like the STAT3 signaling pathway, which promotes malignant behavior, glycolysis, and drug resistance. Natural products and small molecules have been developed for targeting STAT3 signaling in prostate cancer therapy.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Oncology
Canli Yuan, Mei Yuan, Wenyu Li, Hai Cheng, Jianping Luo, Qi Zhang, Mengya Shi, Mingshan Niu, Jiajia Yang, Zengtian Sun, Zhiling Yan, Kailin Xu, Zhenyu Li, Yao Yao
Summary: It was found that targeting the PSMB6 subunit of the 20 S complex could partially overcome resistance to Bortezomib, and the STAT3 inhibitor Stattic was shown to selectively inhibit PSMB6 and induce apoptosis in Bortezomib resistant and sensitive multiple myeloma cells. Therefore, PSMB6 may be a novel target for overcoming Bortezomib resistance, and Stattic may offer a potential therapeutic strategy.
EXPERIMENTAL CELL RESEARCH
(2023)
Article
Environmental Sciences
Vimala Karuppaiya, Asaikkutti Annamalai, Shanthi Krishnamurthy, Kannan Soundarapandian
Summary: This study found that the natural substance DCL can inhibit the proliferation and migration of prostate cancer cells by blocking the JAK/STAT3 signaling pathway. The results showed that DCL has significant cytotoxic effects on PC-3 cells and can increase ROS production and apoptotic signals. Additionally, DCL suppresses the expression of proteins that control cell proliferation.
ENVIRONMENTAL TOXICOLOGY
(2023)
Article
Oncology
Qi Zhao, Yingying Cheng, Ying Xiong
Summary: The study analyzed the immune microenvironment in prostate cancer (PRAD) and identified macrophages, resting mast cells, and plasma cells as key players. It was found that high tumor mutation load was correlated with lymph node metastasis in PRAD patients. The core gene identified, LTF, was shown to play a crucial role in PRAD immune microenvironment and could potentially improve patient survival.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Romana Mikyskova, Olena Sapega, Miroslav Psotka, Ondrej Novotny, Zdenek Hodny, Sona Balintova, David Malinak, Jana Svobodova, Rudolf Andrys, David Rysanek, Kamil Musilek, Milan Reinis
Summary: The responsiveness of proliferating and docetaxel-induced senescent cancer cells to small molecule STAT3 inhibitor Stattic and its analogues was evaluated. Senescent cells were more resistant to these inhibitors and could affect the secretion of certain cytokines. This study provides useful information for further development of STAT3 inhibitor-based therapy for cancer or age-related diseases.
MOLECULAR MEDICINE REPORTS
(2023)
Article
Biotechnology & Applied Microbiology
Yuchen Xia, Guihua Wang, Manli Jiang, Xueting Liu, Yan Zhao, Yinghui Song, Binyuan Jiang, Demao Zhu, Ling Hu, Zhao Zhang, Ting Cao, Ji Ming Wang, Jinyue Hu
Summary: The inhibition of glutathione reductase (GSR) induces cell death in human cervical cancer cells, and the STAT3 inhibitor Stattic also leads to cell death by inhibiting GSR enzyme activity. This induction of cell death is ROS-dependent, and Stattic has potential therapeutic effects in inhibiting the growth of cervical cancer tumors.
ONCOTARGETS AND THERAPY
(2021)
Article
Biochemistry & Molecular Biology
Martha B. Alvarez-Elizondo, Daphne Weihs
Summary: In this study, the invasiveness of CD44(+)ALDH(+) cancer stem-like cells (CSCs) was investigated using a rapid mechanobiology-based assay. It was found that CD44(+)ALDH(+) cells showed higher invasiveness and migratory capacity, suggesting their potential role in disease progression and as prognostic markers for recurrence and metastasis.
CELLULAR AND MOLECULAR LIFE SCIENCES
(2022)
Article
Oncology
Qianghua Zhou, Kaiwen Li, Yiming Lai, Kai Yao, Qiong Wang, Xiangyu Zhan, Shirong Peng, Wenli Cai, Wei Yao, Xingxing Zang, Kewei Xu, Jian Huang, Hai Huang
Summary: Both B7-H3 and HHLA2 have a critical impact on the immunosuppressive microenvironment in PCa. The B7 score, combined with CD8(+) TILs, can be used as a new immune classification to stratify the risk of death, especially cancer-related death, for patients with PCa.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Oncology
Wenyue Yu, Chun Wang, Zhiqun Shang, Jing Tian
Summary: Single-cell RNA sequencing is an advanced technology that provides insights at the individual cell level and is particularly well-suited for identifying rare cell populations. In the context of prostate cancer, a disease characterized by significant heterogeneity and multiple stages of progression, single-cell RNA sequencing emerges as a powerful tool for uncovering its intricate secrets.
FRONTIERS IN ONCOLOGY
(2023)
Review
Immunology
Amr Allam, Marina Yakou, Lokman Pang, Matthias Ernst, Jennifer Huynh
Summary: This article discusses the relationship between cancer-associated fibroblasts (CAFs) and signal transducer and activator of transcription 3 (STAT3) in the tumor microenvironment, as well as their impact on tumor growth, immune suppression, and metastatic spread. Research suggests that CAF-intrinsic STAT3 activity is closely associated with tumor progression.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, Research & Experimental
Lingshuang Sheng, Xiong Wang, Ning Tang, Fankai Meng, Liang Huang, Dengju Li
Summary: This study analyzed 232 cases to illustrate the clinical characteristics of patients with severe COVID-19 in Wuhan and identify notable markers for early clinical warning. Age, comorbidities, platelet count, albumin, D-dimer, LDH, CRP, and IL-6 levels were considered as more meaningful markers for COVID-19 prognostic evaluation.
CLINICAL AND EXPERIMENTAL MEDICINE
(2021)
Article
Oncology
Yuqi Guan, Meilan Zhang, Wei Zhang, Jiachen Wang, Kefeng Shen, Kai Zhang, Li Yang, Liang Huang, Na Wang, Min Xiao, Jianfeng Zhou
Summary: Ph+ ALL accounts for 20-30% of adult ALL patients, with TKIs significantly improving outcomes. Sequential infusion of CD19/22 CAR-T therapy showed promising results in achieving molecular remission, with ddPCR established as a sensitive method for MRD quantification. Patients achieving SMR3 had no recurrence, highlighting the potential of allo-HSCT as a follow-up therapy. ddPCR may serve as an alternative when nucleic acid is limited, and lack of SMR3 could indicate the need for additional treatments.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
Liting Chen, Wei Mu, Jia Gu, Min Xiao, Liang Huang, Miao Zheng, Chunrui Li, Yi Xiao, Jianfeng Zhou, Xiaolu Long
Summary: This study found that TP53-mutated ctDNA levels can serve as a prognostic marker in NHL patients following CAR T-cell therapy, with higher ctDNA levels being associated with poorer outcomes.
Letter
Oncology
Lili Gao, Li Yang, Liang Huang, Yi Xiao, Jinniu Deng, Miao Zheng, Hui Luo, Lijun Jiang, Min Xiao, Chunrui Li, Jianfeng Zhou
CLINICAL AND TRANSLATIONAL MEDICINE
(2021)
Letter
Oncology
Di Wang, Xia Mao, Yimei Que, Menglei Xu, Yuhang Cheng, Liang Huang, Jue Wang, Yi Xiao, Wen Wang, Guang Hu, Shangkun Zhang, Tongcun Zhang, Chunrui Li, Jianfeng Zhou
BLOOD CANCER JOURNAL
(2021)
Article
Multidisciplinary Sciences
Shangkun Zhang, Chaojiang Gu, Lifang Huang, Han Wu, Jiangzhou Shi, Zijian Zhang, Yong Zhou, Jingjiao Zhou, Yang Gao, Jiaxing Liu, Yingqi Leng, Xiyu Liu, Qinxing Zhang, Liang Huang, Xiqin Tong, Ken H. Young, Jiapeng Li, Haichuan Zhu, Tongcun Zhang
Summary: CAR T-cell therapy is a safe and effective treatment for patients with Hodgkin lymphoma and anaplastic large cell lymphoma. In this study, second and third-generation CAR T-cells targeting CD30 were developed and their efficacy and safety were investigated.
SCIENTIFIC REPORTS
(2022)
Editorial Material
Cell & Tissue Engineering
Hao Xu, Qiuxia Lv, Liang Huang, Wenyue Cao, Jue Wang, Fankai Meng, Chunrui Li, Miao Zheng, Liting Chen, Ketao Mu, Jiali Cheng, Li Zhu, Jianfeng Zhou, Yicheng Zhang, Na Wang, Yang Cao
Article
Oncology
Dan Li, Yimei Que, Shengnan Ding, Guang Hu, Wen Wang, Xia Mao, Ying Wang, Chunrui Li, Liang Huang, Jianfeng Zhou, Wei Zhang, Min Xiao
Summary: BCMA-directed CAR-T cell therapy is a disruptive approach for treating R/R MM, but optimization is necessary for maximizing patient benefit. This case study highlights the importance of assessing the expression range of BCMA for the efficacy and safety of BCMA CAR-T therapy. Special attention should be given to patients with extremely high membrane BCMA expression and extremely low sBCMA expression, as well as the prevention and treatment of cytokine release syndrome.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Meeting Abstract
Hematology
Miao Zheng, Peiling Zhang, Yaxian Ma, Yuhan Bao, Hui Luo, Jiachen Wang, Liang Huang
Meeting Abstract
Hematology
Qiuxia Yu, Xiaoying Zhang, Na Wang, Liang Huang, Chunrui Li, Yicheng Zhang, Jianfeng Zhou, Gaoxiang Wang, Yang Cao
Meeting Abstract
Hematology
Xiaoying Zhang, Xingcheng Yang, Chunyan Wang, Liang Huang, Yicheng Zhang, Jia Wei
Meeting Abstract
Hematology
Jin Jin, Jiali Cheng, Na Wang, Liang Huang, Xiaoxi Zhou, Liting Chen, Hui Luo, Tianjiao Liu, Jiao Meng
Article
Biochemistry & Molecular Biology
Chuan Qin, Dai-Shi Tian, Luo-Qi Zhou, Ke Shang, Liang Huang, Ming-Hao Dong, Yun-Fan You, Jun Xiao, Ying Xiong, Wen Wang, Hao Pang, Jing-Jing Guo, Song-Bai Cai, Di Wang, Chun-Rui Li, Min Zhang, Bi-Tao Bu, Wei Wang
Summary: CAR T-cell therapy targeting BCMA shows manageable safety profile and therapeutic potentials for patients with relapsed/refractory AQP4-IgG seropositive NMOSD. Ongoing clinical trial results demonstrate positive outcomes in improving patients' disabilities and quality of life.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2023)
Article
Biochemistry & Molecular Biology
Jia Wei, Min Xiao, Zekai Mao, Na Wang, Yang Cao, Yi Xiao, Fankai Meng, Weimin Sun, Ying Wang, Xingcheng Yang, Liting Chen, Yicheng Zhang, Haichuan Zhu, Shangkun Zhang, Tongcun Zhang, Jianfeng Zhou, Liang Huang
Summary: Alterations in the TP53 gene are associated with poor prognosis in refractory/relapse aggressive B-cell non-Hodgkin lymphoma (r/r B-NHL). CAR19/22 T-cell therapy shows promising results in patients with TP53 alterations, and combining it with autologous stem cell transplantation (ASCT) further improves outcomes.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2022)
Article
Hematology
Yang Cao, Yi Xiao, Na Wang, Gaoxiang Wang, Liang Huang, Zhenya Hong, Li Meng, Xiaoxi Zhou, Jue Wang, Yang Yang, Hao Xu, Shangkun Zhang, Min Xiao, Liting Chen, Miao Zheng, Chunrui Li, Xia Mao, Chaojiang Gu, Tongcun Zhang, Yicheng Zhang, Jianfeng Zhou
Summary: The study evaluated the safety and efficacy of sequential infusion of CD19/22 CAR T cells following HDT-ASCT for patients with R/R aggressive B-NHL, showing an overall response rate of 90.5% and a 2-year progression-free survival rate of 83.3%. No patients were found to be CD19- and CD22-negative, with 97.1% and 68.6% of patients with ongoing complete remission having consistently detectable levels of CAR transgene.
TRANSPLANTATION AND CELLULAR THERAPY
(2021)